10-K: Phio Pharmaceuticals Reports 2024 Results, Highlights Progress in PH-762 Clinical Trial

Phio Pharmaceuticals Corp. files its 10-K report for the fiscal year ended December 31, 2024, detailing financial results and progress in its clinical-stage immuno-oncology programs, particularly the Phase 1b trial of PH-762.

Summary

• Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing immuno-oncology therapeutics using its proprietary INTASYL technology.
• The company's lead candidate, PH-762, is being evaluated in a Phase 1b clinical trial for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
• In 2024, a Safety Monitoring Committee recommended dose escalation for PH-762 after reviewing data from the first and second dose cohorts.
• Complete tumor clearance was reported in 2 patients with cutaneous squamous cell carcinoma in the second cohort.
• The third dose cohort is fully enrolled, and the company expects to complete enrollment of all patients in the study in the third quarter of 2025.
• Phio terminated its Clinical Co-Development Agreement with AgonOx in May 2024.
• The company is focusing its resources on the U.S. clinical trial with PH-762 and has completed the winding down process for its clinical trial in France.
• The company implemented a cost rationalization program in 2023, transitioning from discovery research to product development.
• As of December 31, 2024, Phio had five full-time employees and operates primarily as a remote business with a laboratory facility in Worcester, Massachusetts.
• The company's cash and cash equivalents totaled $5.382 million as of December 31, 2024.
• The company expects to continue to incur net losses for the foreseeable future and will require substantial additional funds to complete its research and development activities.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive clinical results from the PH-762 trial, the company's financial situation and need for future funding introduce uncertainty.

Positives

• Complete tumor clearance was observed in some patients in the PH-762 clinical trial.
• PH-762 has been well tolerated in all patients enrolled in the trial to date.
• The company has completed IND-enabling studies for PH-894.
• The company has a robust cybersecurity program in place.
• The company has a small core management team.
• The company has a total rewards package consisting of base salary and cash target bonus, a comprehensive benefit package and equity compensation.
• Subsequent to year-end, the company completed financings and received total net proceeds of $6,800,000.

Negatives

• The company has a history of net losses and expects to continue to incur net losses for the foreseeable future.
• The company may not be able to remain compliant with the continued listing requirements of The Nasdaq Capital Market.
• The company is dependent on the success of its INTASYL technology, which is unproven and may never lead to approved and marketable products.
• The company's product candidates are in an early stage of development.
• The company relies upon third parties for the manufacture of the clinical supply for its product candidates.
• The company will require substantial additional funds to complete its research and development activities.
• The company's ability to utilize net operating loss carryforwards and other tax benefits may be limited.

Risks

• The company is dependent on the success of its INTASYL technology, which is unproven and may never lead to approved and marketable products.
• The company's product candidates are in an early stage of development and may fail, experience significant delays, never advance in clinical development or not be successful in efforts to identify or discover additional product candidates.
• If the company experiences delays or difficulties in identifying and enrolling patients in clinical trials, it may lead to delays in generating clinical data and the receipt of necessary regulatory approvals.
• The company relies upon third parties for the manufacture of the clinical supply for its product candidates.
• The company's business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in cybersecurity.
• The company is dependent on the patents it owns and the technologies it licenses, and if it fails to maintain its patents or lose the right to license such technologies, its ability to develop new products would be harmed.
• The company will require substantial additional funds to complete its research and development activities.
• The company may not be able to remain compliant with the continued listing requirements of The Nasdaq Capital Market.
• The price of the company's Common Stock has been and may continue to be volatile.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future and will require substantial additional funds to complete its research and development activities. Phio expects to complete enrollment of all patients in the PH-762 study in the third quarter of 2025.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

Phio Pharmaceuticals operates in the competitive immuno-oncology field, facing competition from both large pharmaceutical companies and smaller biotechnology firms. The company's focus on RNAi-based therapeutics and its INTASYL technology positions it within a growing area of cancer research, but it must navigate the challenges of clinical development and regulatory approval to successfully compete.

Comparison to Industry Standards

• The document does not contain any specific comparisons to industry standards.
• The document does not contain any specific comparisons to comparable companies.
• The document does not contain any specific comparisons to comparable projects.
• The document does not contain any specific comparisons to comparable results.

Management Changes

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial results will impact shareholder value.
• Employees: The company's cost rationalization program and financial stability may affect employees.
• Patients: The development of new cancer treatments could benefit patients.
• Suppliers: The company's reliance on third-party manufacturers affects suppliers.
• Creditors: The company's ability to raise additional capital will impact creditors.

Next Steps

• Complete enrollment of all patients in the PH-762 Phase 1b clinical trial in Q3 2025.
• Continue development of immuno-oncology therapeutics based on the INTASYL platform.
• Seek additional funding through equity offerings, debt offerings, and/or strategic opportunities.

Key Dates

Keywords

PH-762, INTASYL, immuno-oncology, clinical trial, PD-1, biotechnology, pharmaceuticals, RNAi, cancer, tumor